Aclarion (NASDAQ:ACON) Releases Quarterly Earnings Results, Misses Estimates By $0.29 EPS

Aclarion (NASDAQ:ACON) announced its earnings results on Wednesday. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29), FiscalAI reports. The company had revenue of $0.02 million during the quarter. Aclarion had a negative return on equity of 83.63% and a negative net margin of 11,238.59%.

Aclarion Stock Performance

Shares of ACON opened at $6.96 on Thursday. The stock has a 50 day moving average price of $7.83 and a 200 day moving average price of $7.40. The stock has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.01 and a beta of 1.42. Aclarion has a one year low of $6.20 and a one year high of $3,499.51.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $11,758.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.